JP2020501589A - がんの治療 - Google Patents

がんの治療 Download PDF

Info

Publication number
JP2020501589A
JP2020501589A JP2019534134A JP2019534134A JP2020501589A JP 2020501589 A JP2020501589 A JP 2020501589A JP 2019534134 A JP2019534134 A JP 2019534134A JP 2019534134 A JP2019534134 A JP 2019534134A JP 2020501589 A JP2020501589 A JP 2020501589A
Authority
JP
Japan
Prior art keywords
herpes simplex
simplex virus
oncolytic herpes
tumor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019534134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020501589A5 (https=
Inventor
コナー，ジョー
クライペ，ティモシー
Original Assignee
ウイルツ・バイオロジクス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1622214.3A external-priority patent/GB201622214D0/en
Priority claimed from GBGB1702565.1A external-priority patent/GB201702565D0/en
Application filed by ウイルツ・バイオロジクス・リミテッド filed Critical ウイルツ・バイオロジクス・リミテッド
Publication of JP2020501589A publication Critical patent/JP2020501589A/ja
Publication of JP2020501589A5 publication Critical patent/JP2020501589A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nuclear Medicine (AREA)
JP2019534134A 2016-12-23 2017-12-22 がんの治療 Pending JP2020501589A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1622214.3 2016-12-23
GBGB1622214.3A GB201622214D0 (en) 2016-12-23 2016-12-23 treatment of cancer
GB1702565.1 2017-02-17
GBGB1702565.1A GB201702565D0 (en) 2017-02-17 2017-02-17 Treatment of cancer
PCT/EP2017/084421 WO2018115458A1 (en) 2016-12-23 2017-12-22 Treatment of cancer

Publications (2)

Publication Number Publication Date
JP2020501589A true JP2020501589A (ja) 2020-01-23
JP2020501589A5 JP2020501589A5 (https=) 2021-02-12

Family

ID=61189397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019534134A Pending JP2020501589A (ja) 2016-12-23 2017-12-22 がんの治療

Country Status (6)

Country Link
US (1) US20200000861A1 (https=)
EP (1) EP3558377A1 (https=)
JP (1) JP2020501589A (https=)
CN (1) CN110869052A (https=)
CA (1) CA3047508A1 (https=)
WO (1) WO2018115458A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018235944B2 (en) * 2017-03-15 2024-01-04 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
AR111432A1 (es) 2017-04-28 2019-07-10 Merck Sharp & Dohme Biomarcadores para agentes terapéuticos contra el cáncer
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
WO2021127556A1 (en) * 2019-12-20 2021-06-24 Board Of Regents, The University Of Texas System Methods for treating cancer comprising low dose radiation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510953A (ja) * 2008-01-31 2011-04-07 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 制御性ｔ細胞活性を抑制するための、ヒトｃｄ３９に対する抗体およびその使用
JP2015524441A (ja) * 2012-08-01 2015-08-24 テトラロジック ファーマシューティカルズ コーポレーション 併用療法
WO2015173544A1 (en) * 2014-05-12 2015-11-19 Virttu Biologics Limited Oncolytic virus and aurora kinase inhibitor for the treatment of cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US20070003520A1 (en) 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2009148488A2 (en) * 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
CA2872652A1 (en) * 2012-05-07 2013-11-14 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
EP3473708B1 (en) * 2012-07-24 2021-01-27 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
EP3217993A1 (en) * 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510953A (ja) * 2008-01-31 2011-04-07 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 制御性ｔ細胞活性を抑制するための、ヒトｃｄ３９に対する抗体およびその使用
JP2015524441A (ja) * 2012-08-01 2015-08-24 テトラロジック ファーマシューティカルズ コーポレーション 併用療法
WO2015173544A1 (en) * 2014-05-12 2015-11-19 Virttu Biologics Limited Oncolytic virus and aurora kinase inhibitor for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUMAN GENE THERAPY, vol. 25(12), JPN6021048919, 2014, pages 5 - 6, ISSN: 0004807311 *

Also Published As

Publication number Publication date
CA3047508A1 (en) 2018-06-28
CN110869052A (zh) 2020-03-06
EP3558377A1 (en) 2019-10-30
US20200000861A1 (en) 2020-01-02
WO2018115458A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
US10813958B2 (en) Use of oncolytic herpes simplex virus, alone or in combination with immune check-point inhibitor, in the treatment of cancer
Thomas et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
Bommareddy et al. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma
Streby et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients
Yun et al. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements
ES2831080T3 (es) Virus oncolítico modificado
US20200171151A1 (en) Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator
JP2020100672A (ja) 固形腫瘍悪性病変を処置するための、抗ｃｔｌａ−４抗体および／または抗ｐｄ−１抗体と組み合わせた、細菌、細菌産物、および他の免疫調節性実体の使用
US20210085734A1 (en) Methods of treating bladder cancer
US20200000861A1 (en) Treatment of cancer
Alvarez-Breckenridge et al. Pharmacologic and chemical adjuvants in tumor virotherapy
TWI817958B (zh) 用於治療肝癌之組合物及方法
JP2023546178A (ja) Ｃｄ１９を標的とする遺伝子操作されたｔ細胞を用いたｂ細胞悪性腫瘍の同種他家細胞療法
Chambers et al. The one health consortium: design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in combination with a checkpoint inhibitor in canine patients with sporadic high grade gliomas
JP2019515948A (ja) 抗がん腫瘍溶解性ウイルス併用療法および優良レスポンダー選択プラットフォーム
US20250032611A1 (en) Gene editing and engineering stem cells for drug delivery
WO2021040056A1 (en) Genetically engineered oncolytic vaccinia viruses and methods of uses thereof
Guinn et al. 8th international conference on oncolytic virus therapeutics
Frendéus et al. Vector-based Cancer Immunotherapy
US20230255978A1 (en) Methods for treating glioblastoma
RU2802962C2 (ru) Композиции и способы лечения рака печени
HK40088121A (zh) 用於治疗胶质母细胞瘤的方法
Denton Modulation of tumor associated macrophages enhances oncolytic herpes virotherapy in preclinical models of Ewing sarcoma
Rakic Oncolytic Vesicular Stomatitis Virus and Sunitinib Combination Therapy for Treating Neuroblastoma
Smith Exploiting the Glioblastoma Tumor Microenvironment for Enhanced Oncolytic Herpes Simplex Virus Therapy

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20200107

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220624